

April 15, 2020



Government **B**ioscience **G**rants

---

THE ESSENTIAL GUIDE TO  
**Coronavirus**  
**Government Funding**

PUBLISHED BY



Questions?

Liz Powell, Esq., MPH


[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)






[www.G2Gconsulting.com](http://www.G2Gconsulting.com)



[@G2Gconsulting](https://twitter.com/G2Gconsulting)



**COVID-19**  
Coronavirus





<http://www.g2gconsulting.com/bioscience-corner>

**\*Special Edition\***  
**Coronavirus Funding and Resources Report**

April 15, 2020

G2G is tracking on a daily basis the coronavirus response funding and legislation. We have been hosting a weekly series of webinars to help businesses, start-ups, nonprofits, and innovative companies and entrepreneurs stay up-to-date on the latest R&D grants, forgivable and low-interest loans, tax credits and other programs and policies enacted to help states, businesses, nonprofits and individuals during this unprecedented time. We are also providing guidance on how to access the billions of dollars in new non-dilutive government funding. Click [here](#) to explore upcoming webinars and to register.

We will continue to provide updates in our [Twitter posts](#) and in our [Legislative Updates](#) and on [G2G's LinkedIn account](#).

In this Report you will find current, upcoming, and past (closed) COVID-19-related funding opportunities and resources listed by agency in alphabetical order. Please let us know any questions by contacting Liz Powell at [lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com).

**TABLE OF CONTENTS**

<b>AGENCY</b>	<b>PAGE</b>	<b>AGENCY</b>	<b>PAGE</b>
Biomedical Advanced Research and Development Authority (BARDA)	2-3	Department of Homeland Security (DHS) Federal Emergency Management Agency (FEMA)	9
Centers for Disease Control and Prevention (CDC)	3	Food and Drug Administration (FDA)	10
DOD Congressionally Directed Medical Research Programs (CDMRP)	4	Non-Governmental Organization (NGO)	10
DOD Medical CBRN Defense Consortium (MCDC)	5	National Institute of Health (NIH)	10-15
DOD Medical Technology Enterprise Consortium (MTEC)	5-6	National Science Foundation (NSF)	16
DOD Small Business Innovation Research (SBIR)	6-7	Office of Science & Technology Policy (OSTP)	16
DOD U.S. Special Operations Command (USSOCOM)	7-8	Small Business Administration (SBA)	17
DOD xTechSearch	8	Other – Biotechnology Innovation Organization (BIO)	17
DOD U.S. Army Medical Research & Development Command (USAMRDC)	9	Other – BioOhio COVID-19 Resources Guide for Bioscience Organizations	17

	Title	Opp. Number	Description	Deadline	Funding Level	Link
			<b>BARDA (3)</b>			
1.	Broad Agency Announcement (BAA)	BAA-18-100-SOL-00003	<p>The BARDA Broad Agency Announcement is entirely focused on Coronavirus responses and the following areas of interest:</p> <ul style="list-style-type: none"> <li>• Diagnostic Assay for human coronavirus using existing FDA-cleared platforms</li> <li>• Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus</li> <li>• Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)</li> <li>• COVID-19 Vaccine</li> <li>• COVID-19 Therapeutics</li> <li>• Immunomodulators or therapeutics targeting lung repair</li> <li>• Pre-exposure and Post-exposure Prophylaxis</li> <li>• Respiratory Protective Devices</li> <li>• Ventilators</li> </ul> <p>BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice.</p>	White Papers Due: 4/30/20, 7/31/20, 10/31/20	Up to \$8 million, Dependent upon proposal	<a href="https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view">https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view</a>
2.	EZ BAA, Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement	BAA-20-100-SOL-0002	<p>To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak. Under the EZ-BAA, BARDA is looking for:</p> <ul style="list-style-type: none"> <li>• Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform</li> <li>• Point-of-care diagnostic assay for detection of SARS-CoV-2 virus</li> <li>• Diagnostic assay for detection of COVID-19 disease</li> <li>• Nonclinical model development and screening for SARS-CoV-2 virus</li> <li>• Alternate vaccine delivery/administration and adjuvants</li> <li>• Advanced manufacturing technologies</li> </ul>	Proposals Accepted on Rolling Basis	Up to \$750,000 for up to 2 years	<a href="https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view?keywords=BAA-20-100-SOL-0002%20&amp;sort=-relevance&amp;index=&amp;is_active=true&amp;page=1">https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view?keywords=BAA-20-100-SOL-0002%20&amp;sort=-relevance&amp;index=&amp;is_active=true&amp;page=1</a>

3.	CoronaWatch Requests	N/A	<p style="text-align: center;"><b>BARDA</b></p> <p>Seeks information from stakeholders on available medical countermeasures in development, particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. Items to submit include: Brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information you think will be helpful. Ideal technologies and products would (but are not required to) be:</p> <ul style="list-style-type: none"> <li>• Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities</li> <li>• Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability</li> <li>• Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)</li> </ul>	On-going	Dependent upon proposal	<a href="https://www.mediccountermeasures.gov/request-barda-techwatch-meeting/">https://www.mediccountermeasures.gov/request-barda-techwatch-meeting/</a>
			<b>CDC (2)</b>			
4.	CDC Programs and Information	N/A	The CDC has several COVID-19 resources and information on its website including: Symptoms and Testing; Frequently Asked Questions; Cases and Surveillance; Schools, Workplaces and Community Locations; Healthcare Professionals; Health Departments; Laboratories; and Communication Resources.	N/A	N/A	<a href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">https://www.cdc.gov/coronavirus/2019-ncov/index.html</a>
5.	(*Closed) Centers for Disease Control COVID-19 Broad Agency Announcement	75D301-20-R-67897	The Centers for Disease Control and Prevention issued this BAA that was open for 14 days starting March 11 and was an immediate call for White Papers addressing the following focus areas: Surveillance, natural history, and household transmission; Diagnostics development and novel technology development and evaluation to improve diagnostic testing and detection; Immune response and transmission dynamics; Host infection dynamics; and Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases (ID/EPB).	Closed: 3/25/20	Dependent upon Proposal	<a href="https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view">https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view</a>

DOD CDMRP (3)						
6.	FY20 Peer Reviewed Medical Program (PRMRP) Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20-PRMRP-CTA-COV	This PRMRP Clinical Trial Award supports rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement. Proposed projects may range from small proof-of- concept trials through large-scale, definitive trials. IND or IDE applications to the FDA, if needed, should be submitted to the FDA before the PRMRP application submission deadline.	Pre-Application Due: 6/8/20  Proposal Due: 6/22/20	Dependent upon proposal, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-CTA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-CTA-COV.pdf</a>
7,	FY20 Peer Reviewed Medical Program (PRMRP) Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20-PRMRP-IIRA-COV	This PRMRP Investigator-Initiated Research Award supports research that will make an original and important contribution to the field of research and/or patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement. A partnering PI option is available and no clinical trials will be funded with this award mechanism.	Pre-Application Due: 5/28/20  Proposal Due: 6/12/20	Up to \$1.6 million, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-IIRA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-IIRA-COV.pdf</a>
8.	FY20 Peer Reviewed Medical Program (PRMRP) Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20-PRMRP-TTDA-COV	This PRMRP Technology/Therapeutic Development Award supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement and must be product-oriented (e.g., device, drug, clinical guidelines) and the product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. Clinical trials will not be funded with this award mechanism.	Pre-Application Due: 5/28/20  Proposal Due: 6/12/20	Up to \$4 million, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-TTDA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-TTDA-COV.pdf</a>

<b>DOD MCDC (1)</b>						
9.	(*Closed) Diagnostics, Surveillance, POC, Therapeutics, Prophylactics, Clinical Trials	N/A	The Medical CBRN Defense Consortium (MCDC) is a consortium of traditional and non-traditional defense contractors, small businesses, for-profit and not-for-profit entities, and academic institutions brought together for rapid prototyping in order to support the Department of Defense's medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. This announcement sought proposals to address COVID-19 in the following technical areas: 1) Prevention (prophylaxis, pretreatment and post-exposure prophylaxis), 2) Detection/Diagnosis (systems and devices to identify CBRN agents and assist in making medical decisions) and 3) Treatment (therapeutics for post-exposure and post-symptomatic).	Closed: 4/6/20	N/A	<a href="https://ati.acqcenter.com/MCDC/BIDS.NSF/Start?ReadForm">https://ati.acqcenter.com/MCDC/BIDS.NSF/Start?ReadForm</a>
<b>DOD MTEC (4)</b>						
10.	Pre-Announcement National Emergency Telecritical Care Network (NETCCN) Project	N/A	This program is specifically focused on preparation for COVID-19 related critical care capability shortages. Although the United States has more critical care beds per capita than other developed nations, emerging national and international experience with COVID-19-related critical illness suggests a high level of oncoming system stress on critical care resources and a likely potential for intensive care unit (ICU) beds and care teams to be overwhelmed. Telecritical care can be a powerful force-multiplier in the extension of limited critical care resources in both high-census urban centers and rural communities in which access to critical care – facilities, equipment and trained clinicians – is limited even under normal conditions. The vision for this program is to extend local telecritical care capability sets to a broader, flexible network – first locally, then step-wise regionally and nationally – that can be leveraged wherever there is need. This upcoming RPP will focus on enhanced development of integrated technologies and clinical workflows to establish and rapidly scale virtual wards.	To be determined	Dependent upon proposal	<a href="https://www.mtec-sc.org/upcoming-solicitations/">https://www.mtec-sc.org/upcoming-solicitations/</a>
11.	Upcoming Funding Announcements at MTEC	N/A	MTEC funding announcements related to the following topic areas are expected to be released soon and will require quick responses to meet timelines for the award: Telehealth Patient Management to Monitor and Direct Care to Non-hospital Settings; Treatment of COVID-19 Related Severe Acute Respiratory Distress Syndrome and Acute Lung Injury; Technologies to Reduce Medical Workforce Burden and Maximize Resources Utilization.	To be determined	Dependent upon proposal	<a href="https://www.mtec-sc.org/upcoming-solicitations/">https://www.mtec-sc.org/upcoming-solicitations/</a>

12.	Potential Topics for Upcoming Funding Announcements at MTEC	N/A	<p style="text-align: center;"><b>DOD MTEC</b></p> <p>MTEC anticipates the potential for additional funding announcements related to the following topic areas:</p> <ul style="list-style-type: none"> <li>• Point-of-Care Diagnostics to Rapidly ID Infected Individuals.</li> <li>• Predictive Analytics that can Forecast Potential Hot Spots and Empower Decision Makers Response Actions.</li> </ul>	To be determined	Dependent upon proposal	<a href="https://www.mtec-sc.org/upcoming-solicitations/">https://www.mtec-sc.org/upcoming-solicitations/</a>
13.	(*Closed) Development of Treatments for COVID-19	MTEC-20-09-COVID-19_Treatment_MIDRP	This solicitation sought proposals for: Therapeutic(s) that can treat COVID-19; Treatments with potential application to the prevention of COVID-19 infection were desired; and Therapeutics that can be administered in a non-hospital environment were desired.	Closed: 4/8/20	Up to \$4 million, for up to 8 months	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/03/20-09-COVID19_RPP.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/03/20-09-COVID19_RPP.pdf</a>
			<b>DOD SBIR (3)</b>			
14.	Small Business Innovation Research (SBIR) Program X20.R SBIR Commercial Solutions Opening (CSO) Air Force Ventures Direct to Phase II	AF20R-DCSO1	The Air Force COVID-19 Operational Planning Team (OPT) has assembled to identify key interest areas supporting COVID-19 defeat and mitigation related to AF operations and activities. The areas of interest include: <b>Decision Support in Combating the Virus</b> (Social Media Analytics, Adware Proximity Algorithm, Mobile Application for Self-Reporting, Enterprise Tool for COVID Tracking); <b>Personnel Needs</b> (Tele-Ministry, Tele-Counseling, Tele-Health, ChatBots); <b>Readiness</b> (Readiness Impact Assessment Tools, Training Scheduling Optimization Tools); <b>Logistics</b> (Medical Resources Common Operational Picture to provide shared supply/demand for critical supplies and deploy AI to enable forecasting, match timing, and supply types with vendor and delivery method); <b>Medical</b> (Air and Surface Cleansing, COVID-19 Testing & Management and Medical Supply Chain); <b>Blue Sky</b> (Solutions other than those listed above)	Proposals Due: 4/30/20	Up to \$1 million for up to 27 months	<a href="https://beta.sam.gov/opp/aa1fc86c0cde4352a8ca464ee5b3296c/view#description">https://beta.sam.gov/opp/aa1fc86c0cde4352a8ca464ee5b3296c/view#description</a>  <a href="https://www.afwerx.af.mil/sbir.html">https://www.afwerx.af.mil/sbir.html</a>  <a href="https://www.dodsbirsttr.mil/submissions/login">https://www.dodsbirsttr.mil/submissions/login</a>

15.	Department of the Navy (DON) SBIR Defense Industrial (DIB) Technology Acceleration	N/A	<p style="text-align: center;"><b>DOD SBIR</b></p> <p>The Department of Navy seeks digital logistic support to ensure dynamic, reliable, and robust delivery of medical supplies, support and care. The logistics of providing medical supplies, support, and care during mass illness and casualties, whether due to pandemics like COVID-19 or natural disasters or war, faces numerous challenges, including knowledge of supply chains that provide raw materials to manufacturers, ability for manufactures to increase production rates or retool their factories to produce medical products, ability to obtain FDA approval, if required, and ability to obtain federal, state, and local government contracts in a timely manner. The Department of the Navy (DON) is also urgently seeking portable, small form factor communications capabilities that meet the requirements for rapid and coordinated response during the COVID-19 crisis.</p>	Proposal Due: 5/28/20	Up to \$150,000, for up to 5 months for Phase I and up to \$1.7 million, for Phase II	<a href="https://www.navy.sbir.com/docs/NAVY-20.4-BAA-20200410_Final.pdf">https://www.navy.sbir.com/docs/NAVY-20.4-BAA-20200410_Final.pdf</a>
16.	Department of the Navy (DON) SBIR/STTR – COVID-19 Pivot	N/A	The Department of Navy is soliciting SBIR/STTR abstracts for proposals addressing the ongoing COVID-19 pandemic. Send 250-word abstract to the Navy SBIR/STTR via email with the Subject line: “COVID-19 Pivot” to <a href="mailto:navy-sbir-sttr@navy.mil">navy-sbir-sttr@navy.mil</a>	Proposals Accepted on Rolling Basis	Dependent upon Proposal	<a href="mailto:navy-sbir-sttr@navy.mil">navy-sbir-sttr@navy.mil</a>
<b>DOD USSOCOM (2)</b>						
17.	(*Closed) SOCOM COVID-19 Innovation Challenge	N/A	The Coronavirus (COVID-19) outbreak was declared a national emergency in the United States in accordance with section 201 of the National Emergencies Act. The Secretary of Defense announced several measures to protect the Joint Force and the Public and U.S. Commanders received delegated authority to make further decisions based on their own assessments in order to protect their people and ensure mission readiness. This open call for innovative capabilities addressed the impacts of COVID-19 on public safety and national security. The innovations and solutions collected will be shared by default with a wide network of Government personnel engaged in the current challenge.	Closed: 3/31/20	N/A	<a href="https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome">https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome</a>  (Must create free account at Vulcan link to access SOCOM announcements and to make submissions)



18.	(*Closed) SOCOM DIY Hack-a-Vent Innovation Challenge	N/A	<p style="text-align: center;"><b>DOD USSOCOM</b></p> <p>This Innovation Challenge sought low-cost, non-FDA approved, mechanical ventilation support systems that can be rapidly produced at local levels with widely available resources. The top 3 submissions were selected by a panel of experts and may be offered an opportunity to produce a functioning prototype by March 30, 2020.</p>	Closed: 3/25/20	N/A	<p><a href="https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome">https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome</a></p> <p>(Must create free account at Vulcan link to access SOCOM announcements and to make submissions)</p>
<b>DOD xTECHSEARCH (2)</b>						
19.	Army xTechSearch COVID-19 Ventilator Challenge	N/A	<p>The Army seeks a low-cost, readily manufacturable emergency ventilator to quickly augment ventilator capacity in the exigent COVID-19 pandemic. The technology solution must provide a rapid response breathing apparatus capable of short-term, rugged field operation. In addition, the ventilator must be low cost, require minimal components, with a small footprint, and designed for mass production. Ideally, the technology would support field hospitals that are still acquiring critical infrastructure such as generators, power distribution and pressurized oxygen. The objective capabilities include: Readily manufacturable materials and parts; Accommodate standard hoses and fittings; Respiratory rate of 0 to 60 bpm; Tidal volume of 50 to 1000 mL; Ability to measure and control peak inspiratory pressure; Adjustable inspiratory to expiratory time ratio; Ability to support triggered breaths; Provides Positive End Expiratory Pressure (PEEP); Able to use ambient air, or low pressure oxygen; Able to operate off generator power sources; Able to trigger alarms for key critical parameters, such as disconnect from patients, apnea, pressure, power failures.</p>	Open Now	Up to \$100,000 per award	<p><a href="https://www.arl.army.mil/xtechsearch/">https://www.arl.army.mil/xtechsearch/</a> (Background Information)</p> <p><a href="https://usg.valideval.com/teams/xTech_covid_vent/signup">https://usg.valideval.com/teams/xTech_covid_vent/signup</a> (Registration and Submission portal)</p>
20.	(*Closed) Army xTechSearch Medical Technologies	N/A	<p>This opportunity requested technologies optimized for use in austere environments that prevent, diagnose, treat, mitigate, or cure infectious diseases, including COVID-19 in service members and/or provide immediate cardiopulmonary stabilization and advanced, autonomous life support.</p>	Closed: 3/31/20	N/A	<p><a href="https://www.arl.army.mil/xtechsearch/">https://www.arl.army.mil/xtechsearch/</a></p>

			<b>DOD COVID-19 EMERGENCY PANDEMIC RESPONSES (1)</b>			
21.	Department of Defense Group Email	N/A	During the COVID-19 Coronavirus Emergency Pandemic Response period, industry and academia can send inquiries on how your company or institution can support the response to the DOD's Group Email Box (see column at right for the email address)	On-going	N/A	<a href="mailto:osd.pentagon.ousd-a-s.mbx.covid-19-industry@mail.mil">osd.pentagon.ousd-a-s.mbx.covid-19-industry@mail.mil</a>
			<b>DOD USAMRDC (1)</b>			
22.	New Products and Ideas (NPI)	N/A	The United States Army Medical Research and Development Command (USAMRDC) utilizes the NPI system as a mechanism to have visibility and evaluate new products and ideas, currently configured or in development. The NPI provides a means for DoD subject matter experts to assess these products and ideas, evaluate their applicability to USAMRDC's mission, and provide feedback to the submitter. It provides the vendor an opportunity to showcase their product or idea without needing to travel to Fort Detrick and without giving anyone an unfair competitive advantage. For submissions related to the current COVID-19 (Coronavirus) outbreak, please be sure to select the "Ideas/Products Related to Current COVID-19 Outbreak" category during the "Select a Submission Category" step.	Proposals Accepted on Rolling Basis	N/A	<a href="https://mrdc-npi.amedd.army.mil">https://mrdc-npi.amedd.army.mil</a>
			<b>DHS FEMA (2)</b>			
23.	COVID-19 PPE and Medical Supplies	70FA202 0R000000 11	This is a standing solicitation issued under unusual and compelling needs from which the Government contemplates multiple awards of IDIQs and/or Direct Contracts, Purchase Orders, and Blanket Purchase Agreements for the supplies deemed as urgent in the COVID-19 pandemic. Supplies include materials for diagnostics and testing, RNA extraction, general medical equipment and PPE.	On-going until 9/25/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/3e05e664e606486ca34d1a41b47ff0ff/view">https://beta.sam.gov/opp/3e05e664e606486ca34d1a41b47ff0ff/view</a>
24.	COVID-19 Offer of Medical Supplies or Equipment	1660-0147	Donations of PPE – FEMA is working to marshal every source of medical supplies and equipment, and will work to facilitate your generous donation to ensure the availability of critical protective and lifesaving resources to the right place, at the right time, and in the right quantity for a Whole of Nation response to COVID-19.	On-going until 10/31/20	N/A	<a href="https://www.fema.gov/covid19offers">https://www.fema.gov/covid19offers</a>

FDA (1)						
25.	Coronavirus Treatment Acceleration Program (CTAP)	NA	The FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. The FDA continues to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. <b>Send requests for product development for proposed COVID-19 uses and drug development to: <a href="mailto:COVID19-productdevelopment@fda.hhs.gov">COVID19-productdevelopment@fda.hhs.gov</a>.</b>	On-going	Dependent upon proposal	<a href="https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap">https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap</a>
NGO (1)						
26.	COVID-19 Therapeutics Accelerator	N/A	Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator is a philanthropic initiative designed to coordinate R&D efforts, remove barriers to drug development and scale up treatments to address the pandemic. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. <b>To learn more about the funding process, or how to invest in the accelerator, contact <a href="mailto:therapeuticsaccelerator@gatesfoundation.org">therapeuticsaccelerator@gatesfoundation.org</a>.</b>	Open Now	Dependent upon proposal	<a href="https://www.therapeuticsaccelerator.org">https://www.therapeuticsaccelerator.org</a> (Background Information)  <a href="mailto:therapeuticsaccelerator@gatesfoundation.org">therapeuticsaccelerator@gatesfoundation.org</a> . (Send email to above address to learn more about the funding process)
NIH (10)						
27.	Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	PA-20-135 NOT-AI-20-034	In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address research areas of interest including: Studies to identify optimal <i>in vitro</i> culture requirements and conditions; Development of reagents and assays for virus characterization; Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies; Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence. Click <a href="#">here</a> for the full list of research areas of interest.	On-going	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html</a>

28.	Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)	PA-18-935  NOT-GM-20-025	<p style="text-align: center;"><b>NIH</b></p> <p>The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full FOA that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-GM-20-025.</p>	On-going until 2/5/21	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html">https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html</a>
-----	---	--------------------------------	--	-----------------------	-------------------------	--

29.	Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)	NOT-ES-20-014 PA-20-135 RFA-ES-19-003 RFA-ES-19-004 RFA-ES-19-009 RFA-ES-15-018	<p style="text-align: center;"><b>NIH</b></p> <p>The purpose of this supplement is to provide support for the conduct of worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties. The NIEHS Superfund Worker Training Program (WTP) will work collaboratively to develop and target safety and health training for those workers supporting the national Coronavirus response. Using our hazmat trainers' understanding of worker safety and health protection issues, knowledge of personal protective equipment (PPE) usage, and experience in training disaster workers, WTP will coordinate with the Centers for Disease Control and Prevention (CDC), the Occupational Safety and Health Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH) to provide awardees with material to develop an evidence-based curriculum that addresses the science of Coronavirus (clinical symptoms, mode of transmission, persistence in the environment, and treatment); infection control and worker protection (isolation/quarantine and PPE); working in the contaminated environment (sampling and decontamination); and behavioral health.</p>	Proposal Due: 4/24/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-014.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-003.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-004.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-009.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-es-15-018.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-es-15-018.html</a>
-----	--	--	--	-----------------------	-------------------------	---

30.	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	NOT-HG-20-030 PA-18-591 PA-18-935	<p style="text-align: center;"><b>NIH</b></p> <p>A better understanding of the host response, associated disease, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2. For NHGRI grantees only (including those with a current extension of funds or a no cost extension), we encourage the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: <a href="#">PA-18-935</a> Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant. <a href="#">PA-18-591</a> Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.</p>	On-going until 5/15/20	Up to \$250,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>
31.	Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-AG-20-022 PA-18-591 PA-18-935	<p>NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following research areas of interest in the Divisions of Aging Biology (DAB), Neuroscience (DN), Geriatrics and Clinical Gerontology (DGCG) and Behavioral and Social Research (DBSR)</p>	Proposals Accepted on Rolling Basis until 5/1/21	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>

32.	Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)	PAR-19-099; 100 NOT-TR-20-011	<p style="text-align: center;"><b>NIH</b></p> <p>The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from three or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination outside the CTSA Program consortium if appropriate. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-TR-20-011 Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need).</p>	<p>Letter of Intent Due: 6/10/20, 10/9/20, 2/8/21</p> <p>Proposal Due: 7/10/20, 11/9/20, 3/8/21</p>	Up to \$750,000, for up to 4 years	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-100.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-100.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html</a></p>
33.	Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)	PAR-19-337 NOT-TR-20-011	This FOA is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active Clinical and Translational Science Award (CTSA) Program hub awards (UL1) to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program and are beyond the original scope of the approved parent project Under this competitive revision, only applications for revisions to the UL1 award are allowed. Revisions to the linked KL2 and/or the TL1 awards are not allowed. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-TR-20-011 (Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need).	<p>Letter of Intent Due: 8/25/20</p> <p>Proposal Due: 9/25/20</p>	Up to \$750,000 per year, for up to 3 years	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html</a></p>

34.	Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)	PAR-17-465 NOT-TR-20-012	<p style="text-align: center;"><b>NIH</b></p> <p>This FOA invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase I trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19))</p>	<p>Letter of Intent Due: 5/25/20</p> <p>Proposal Due: 6/26/20</p>	<p>Up to \$200,000 per year, for up to 2 years</p> <p>Dependent upon Funding Mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-17-465.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-17-465.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>
35.	Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)	PAR-18-462 NOT-TR-20-012	<p>The purpose of this FOA is to support clinical trial planning for studies that will evaluate a therapeutic/indication pair for drug repurposing. The repurposing hypothesis should be generated using a developed method that is publicly available. Examples include independent crowdsourcing strategies or any website that lists experimental therapies (drugs or biologics) or use of computational algorithms. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19))</p>	<p>Letter of Intent Due: 5/16/20, 9/16/20</p> <p>Proposal Due: 6/16/20, 10/16/20</p>	<p>Up to \$225,000 per year, for 1 year</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-18-462.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-462.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>
36.	Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)	PAR-18-332 NOT-TR-20-012	<p>This FOA invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19))</p>	<p>Letter of Intent Due: 5/5/20, 9/5/20</p> <p>Proposal Due: 6/5/20, 10/5/20</p>	<p>Up to \$3 million per year, for up to 3 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-18-332.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-332.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>



NSF (1)						
37.	Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)	NSF 20-052	In light of the emergence and spread of COVID-19 in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge encourages the research community to respond to this challenge through <a href="#">existing funding opportunities</a> . In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to \$200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to <a href="mailto:rapid-covid19@nsf.gov">rapid-covid19@nsf.gov</a> .	On-going	Up to \$200,000 for up to 1 year	<a href="https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp">https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp</a>  <a href="https://www.nsf.gov/pubs/policydocs/ppg19_1/index.jsp">https://www.nsf.gov/pubs/policydocs/ppg19_1/index.jsp</a>
OSTP (1)						
38.	COVID-19 Open Research Dataset (CORD-19)	N/A	In response to the COVID-19 pandemic, the Allen Institute for AI has partnered with leading research groups to prepare and distribute the COVID-19 Open Research Dataset (CORD-19), a free resource of over 51,000 scholarly articles, including over 40,000 with full text, about COVID-19 and the coronavirus family of viruses for use by the global research community. This dataset is intended to mobilize researchers to apply recent advances in natural language processing to generate new insights in support of the fight against this infectious disease. The corpus will be updated weekly as new research is published in peer-reviewed publications and archival services like bioRxiv, medRxiv, and others.	N/A	N/A	<a href="https://pages.semanticscholar.org/coronavirus-research">https://pages.semanticscholar.org/coronavirus-research</a>

<b>SBA (1)</b>						
39.	Coronavirus (COVID-19): Small Business Guidance & Loan Resources	N/A	The U.S. Small Business Administration is offering designated states and territories low-interest federal disaster loans for working capital to small businesses suffering substantial economic injury as a result of the Coronavirus (COVID-19). Upon a request received from a state's or territory's Governor, the SBA will issue under its own authority, as provided by the Coronavirus Preparedness and Response Supplemental Appropriations Act that was recently signed by the President, an Economic Injury Disaster Loan declaration. Responses can be expected within 3 weeks. In addition to traditional SBA funding programs, the CARES Act established several new temporary programs to address the COVID-19 outbreak. These include the Paycheck Protection Program, EIDL Loan Advance, SBA Express Bridge Loans, and SBA Debt relief. Click <a href="#">here</a> for more details.	On-going until 6/30/20	Up to \$10,000 in short term Emergency Injury Disaster Loans	<a href="https://www.sba.gov/disaster-assistance/coronavirus-covid-19">https://www.sba.gov/disaster-assistance/coronavirus-covid-19</a>  <a href="https://www.sba.gov/page/coronavirus-covid-19-small-business-guidance-loan-resources#section-header-0">https://www.sba.gov/page/coronavirus-covid-19-small-business-guidance-loan-resources#section-header-0</a>
<b>OTHER (2)</b>						
40.	Biotechnology Innovation Organization (BIO) Coronavirus Hub to Facilitate Exchange of Supplies & Services	N/A	There is a dire need to ensure critical research and development programs can continue. To accomplish this, BIO created the <i>Coronavirus Hub</i> to connect companies with capacity and resources with those that need them. This new hub enables users to post requests for urgently needed items and announce the availability of supplies and capacity. The portal connects in real-time through customized and searchable postings.	On-going	N/A	<a href="https://hub.bio.org">https://hub.bio.org</a>
41.	BioOhio COVID-19 Resources Guide for Bioscience Organizations	N/A	Stay up-to-date with the latest information from government agencies, BioOhio members and partners, and other helpful organizations. If we follow the science, and take appropriate precautions, every one of us can play a role in keeping the infection curve down.	On-going	N/A	<a href="https://www.bioohio.com/covid19/">https://www.bioohio.com/covid19/</a>